Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
6
×
boston blog main
life sciences
national blog main
boston
boston top stories
drugs
rna interference
clinical trials
new york blog main
fda
national top stories
new york top stories
patisiran
akcea therapeutics
aminolevulinic acid
barry greene
biotech
dan ollendorf
givosiran
harvard pilgrim health care
hereditary transthyretin amyloidosis
inotersen
institute for clinical and economic review
onpattro
regeneron pharmaceuticals
san diego blog main
san diego top stories
san francisco blog main
tafamidis
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alirocumab
amgen
amy schulman
andreas klein
anna greka
boston university
What
rna
6
×
alnylam
drug
interference
medicine
fda
pharmaceuticals
rnai
ago
data
gene
market
medicines
new
second
seek
speedy
uses
approval
approve
approves
aren’t
awaits
based
biological
car
cells
cholesterol
cleared
crossed
cutting
decades
decision
discovered
edge
ema
employ
europe
evidence
experiments
Language
Current search:
rna
×
" alnylam pharmaceuticals "
×
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”